Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate UpdateGlobeNewsWire • 02/08/24
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaGlobeNewsWire • 02/02/24
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023GlobeNewsWire • 12/07/23
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/02/23
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature MetabolismGlobeNewsWire • 09/28/23
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of PhenylketonuriaGlobeNewsWire • 07/11/23
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics ForumGlobeNewsWire • 06/27/23
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of PhenylketonuriaGlobeNewsWire • 06/05/23